RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncternal Therapeutics Stock

Oncternal Therapeutics Employees 2024

Oncternal Therapeutics Employees

12

Ticker

ONCT

ISIN

US68236P1075

WKN

A2PL3P

In 2024, Oncternal Therapeutics employed 12 people, a 0% change from the 12 number of employees in the previous year.

Oncternal Therapeutics Aktienanalyse

What does Oncternal Therapeutics do?

Oncternal Therapeutics Inc is an American biotechnology company specializing in the development of cancer drugs. The company was founded in 2013 and is headquartered in San Diego, California. Oncternal Therapeutics' business model is based on identifying promising cancer drugs and advancing them through the approval process of regulatory authorities. The company utilizes both public and private funds to finance its research projects. As part of this, Oncternal Therapeutics participates in clinical trials and actively collaborates with experts in the clinical field. Over the years, the company has established several divisions to make its work more effective and efficient. One of these divisions focuses on developing molecules that activate the body's immune system against cancer cells. A prime example of this is the drug Cirmtuzumab. This antibody blocks signals that promote the growth of cancer cells while simultaneously activating the immune system to target tumor cells. Cirmtuzumab has shown positive results in the treatment of chronic lymphocytic leukemia, a form of blood cancer. Another division of Oncternal Therapeutics focuses on developing drugs that target cancer stem cells. These cells are responsible for the growth and spread of cancer cells in the body. Medications like the ROR1-targeting CAR-T preparation directly target these types of cancer cells and are intended to make cancer drugs more effective and targeted. Oncternal Therapeutics stands out from other cancer researchers in its ability to treat multiple myelomas, a cancer of the bone marrow cells, more effectively. The company has developed specific drugs that can influence the expression of specific genes in myeloma cells, thereby halting tumor growth. Key myeloma products from Oncternal Therapeutics include the TK216 and OT-82 preparations. In summary, Oncternal Therapeutics Inc is an innovative biotechnology company specializing in the development of cancer drugs. The company has a wide range of divisions, from developing drugs that activate the immune system against cancer cells to targeting cancer stem cells. The company's products show promising results in the treatment of various types of cancer and have the potential to bring about positive change for thousands of cancer patients worldwide. Oncternal Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Oncternal Therapeutics's Employee Base

Oncternal Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Oncternal Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Oncternal Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Oncternal Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Oncternal Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Oncternal Therapeutics stock

How many employees does Oncternal Therapeutics have this year?

Oncternal Therapeutics has 12 undefined employees this year.

How many employees did Oncternal Therapeutics have compared to the previous year?

Compared to the previous year, Oncternal Therapeutics had 0% more employees.

What impact did the number of employees have on the company Oncternal Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Oncternal Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Oncternal Therapeutics?

The number of employees can also have an impact on investors of Oncternal Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Oncternal Therapeutics affect the company?

An increase in equity of Oncternal Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Oncternal Therapeutics's equity affect the company?

A reduction in equity of Oncternal Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Oncternal Therapeutics?

Some factors that can influence the equity of Oncternal Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Oncternal Therapeutics so important for investors?

The equity of Oncternal Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Oncternal Therapeutics influence the company?

The number of employees at Oncternal Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Oncternal Therapeutics evolved in recent years?

In recent years, the number of employees at Oncternal Therapeutics has changed by 0.

How many employees does Oncternal Therapeutics currently have?

Oncternal Therapeutics currently has 12 undefined employees.

Why is the number of employees important for investors of Oncternal Therapeutics?

The number of employees is important for investors of Oncternal Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Oncternal Therapeutics take to change the number of employees?

To change the number of employees, Oncternal Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Oncternal Therapeutics pay?

Over the past 12 months, Oncternal Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncternal Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Oncternal Therapeutics?

The current dividend yield of Oncternal Therapeutics is .

When does Oncternal Therapeutics pay dividends?

Oncternal Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncternal Therapeutics?

Oncternal Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Oncternal Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncternal Therapeutics located?

Oncternal Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncternal Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncternal Therapeutics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Oncternal Therapeutics pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Oncternal Therapeutics in the year 2023?

In the year 2023, Oncternal Therapeutics distributed 0 USD as dividends.

In which currency does Oncternal Therapeutics pay out the dividend?

The dividends of Oncternal Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncternal Therapeutics

Our stock analysis for Oncternal Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncternal Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.